Cases
Representative Matters: Mergers
Acquisitions: Represented Onspira in its acquisition by Altavant Sciences GmbH for $10 million, plus milestones
royalties.
Represented investors in connection with the acquisition of a majority interest in a licensed grower
distributor of cannabis in Louisiana.
Represented the shareholders of Teletronics Technology Corporation in the sale of the company to Curtis-Wright Controls for $233 million.
Represented Vicept Therapeutics in its acquisition by Allergan for a $75 million cash up-front payment plus up to an additional $200 million in milestone payments, as well as (undisclosed) sales earnouts.
Represented biopharmaceutical company Ception Therapeutics in its acquisition by Cephalon for $250 million
up to $500 million in milestone payments.
Represented Ception Therapeutics in a $100 million option agreement with Cephalon, pursuant to which Cephalon acquired an option to purchase all of the stock of Ception.
Represented shareholders in the $200 million sale of stock of the holding company of a major media company (Fortune 100)
related reorganization.
Represented Ception Therapeutics in its merger with Fulcrum Pharmaceuticals.
Represented a mortgage insurance company in the divestiture of a structured-settlements subsidiary ($26.5 million).
Cross-Border Mergers
Acquisitions: Represented a French listed company in its acquisition of a Hong Kong
US-based textile manufacturer
distributor for $66 million.
Represented a Quebec company in connection with its acquisition of the assets of a U.S. stone mining company.
Represented a pharmaceutical company in connection with the disposition of the rights to certain EU-approved drugs to a French pharmaceutical company.
Represented a major French transportation company in the $12 million divestiture of a majority interest in a charter bus company.
Represented a major French transportation company in connection with the acquisition of minority interests in a transportation company held by shareholders/managers for an undisclosed amount.
Represented a French listed company in connection with the acquisition of a U.S. manufacturer of surface protection films for $22 million.
Represented a US pharmaceutical company in connection with the disposition of certain drug assets to a South African company for $14 million.
Represented the shareholders of a Quebec-based company operating in the diet industry in connection with the acquisition of a majority interest by a major U.S. private equity firm in a transaction valued at CAD $563 million.
Represented a major French transportation company in connection with the acquisition of a U.S. sightseeing business for an undisclosed amount.
Represented a major French sports management company in connection with the acquisition of a golf events management company for an undisclosed amount.
Represented Ceptaris Therapeutics in its acquisition by Actelion (Switzerl
) for $250 million cash plus undisclosed milestone payments
sales earnouts.
Represented a French CAC 40 company in connection with the sale of its wind-to-energy subsidiary for $81 million.
Represented Iroko Holdings S.A. (Luxembourg) in its acquisition of iCeutica Inc. (Australia), a nanotechnology platform company, for an undisclosed amount.
Represented a UK company, Science Navigation Group, in connection with the divestiture of its Israeli navigation software subsidiary, Telmap, to Intel (for a reported $300 million).
Represented a major Canadian (TSX) company in connection with numerous acquisitions of companies in the US.
Represented a major US public pension fund in connection with a $100 million preferred stock investment in an Irish company.
Represented a major US public pension fund in connection with a $40 million convertible notes investment in an Irish company.
Represented a listed French company in connection with several acquisitions in the US in the telecommunications field.
Represented a listed French company in connection with $110 million acquisition in the surface protection industry.
Represented a US subsidiary of major French minerals company in connection with several investments in China.
Represented a major US engineering design software company in connection with its acquisition of Canadian software company.
Represented a US manufacturer in connection with the purchase of an interest in a Hungarian company.
Represented a US pharmaceutical company in connection with a $26 million joint venture with a South African company relating to the worldwide distribution of a drug.
Represented US shareholders in connection with the divestiture of their interests in a privately owned German software company.
Represented a major French company (CAC 40) in connection with several acquisitions in the US.
Advised a major French company (CAC 40) in connection with a large potential claim ($1.5 billion) from a counterparty in an M&A dispute.
Represented a UK company in connection with the sale of a gold mine in Tanzania to a Chinese acquirer.
Venture Capital
Private Equity: Represented a start-up diagnostics company in connection with the acquisition of intellectual property from a university
$3 million seed raise.
Represented Velicept Therapeutics, a specialty pharmaceutical company, in its acquisition of AltheRx, Inc.
$20 million Series B financing.
Represented a start-up oncology company in connection with a $1 million convertible notes seed raise.
Represented a start-up artificial intelligence company in connection with a $500,000 convertible notes seed raise.
Represented a start-up pharmaceutical company in connection with a $1 million secured convertible promissory notes issue.
Represented an artificial intelligence company in connection with a $4.6 million series B financing.
Represented Ralexar Therapeutics in connection with a $6.9 million Series B financing.
Represented Velicept Therapeutics in connection with a convertible notes financing.
Represented Aclaris Therapeutics, Inc., a specialty pharmaceutical company with a focus on the development of novel topical dermatological therapies, in connection with the sale of $21.3 million of Series B Preferred Stock.
Represented Ralexar Therapeutics in connection with a $21.5 million Series A financing.
Represented a major French media company in connection with a $20 million Series A financing for a U.S. publisher of music, sports
entertainment web applications.
Represented Aclaris Therapeutics in a $21 million Series A financing.
Represented a pain pharmaceutical company in a $3 million Series A financing.
Represented Ceptaris Therapeutics in a $10 million Series D-1 financing.
Represented Ceptaris Therapeutics in a $14.4 million Series D financing.
Represented Ception Therapeutics in a $77 million Series C financing.
Represented a start-up pharmaceutical company in connection with angel-investor funding.
Represented Vicept Therapeutics in two rounds of Series A financing, which raised a total of $16 million.
Financings: Represented Ceptaris Therapeutics, Inc. in connection with $15 million venture debt financing.
Represented Ception Therapeutics in a $12 million venture debt financing.
Represented Vicept Therapeutics in a $2.5 million venture debt financing.
Represented a manufacturer of avionics in $10 million
$3 million bank loan facilities.
Represented a Fortune 100 company in connection with $245 million project financing involving aircraft
a data-processing facility.
Represented a real estate development company in connection with a $25 million secured bank loan facility.
Represented a Fortune 100 logistics
transportation company in connection with various over-the-counter (OTC) swaps, including interest-rate derivatives, foreign-currency derivatives
equity derivatives conducted pursuant to the International Swaps
Derivatives Association (ISDA).
Represented a Fortune 100 company in connection with a $1.5 billion revolving loan facility.
Represented a Fortune 100 company in connection with a $1 billion revolving loan facility.
Cross-Border Financings: Represented a major Canadian bank in connection with a secured lending facility to a Quebec company for purposes of an acquisition in the US.
Represented a listed French company
its U.S. holding company in connection with a $17 million secured loan from a major U.S. bank.
Represented a pharmaceutical company in connection with a $140 million secured debt financing,
the restructuring thereof.
Represented a major French CAC 40 company as lender
guarantor in connection with a $230 million project syndicated loan to a wind energy project.
Represented Iroko Pharmaceuticals in connection with a cross-border $90 million secured debt financing.
Represented a major French company (CAC 40) in connection with guarantees related to two wind energy projects developed by a US subsidiary ($175 million
$63 million).
Represented a major Canadian company in connection with secured loans extended by Canadian banks
guaranteed by US subsidiaries of Canadian company (US$400 million
US$200 million
US$75 million).
Represented a listed French company in connection with a secured $110 million cross-border facility extended by French banks
guaranteed by US subsidiaries.
Represented a subsidiary of a major French company (CAC 40) in connection with a $107 million extension of a letter of credit supporting a waste-to-energy project.
Represented a major French company (CAC 40)
its US subsidiary in connection with a $130 million project financing for a waste-to-energy plant.
Represented a major US public pension fund in connection with $4.7 billion restructuring of debt of Irish company.
Represented a major US pension plan in connection with $120 million convertible notes issued by an Irish company.
Represented a Canadian company in connection with $5 million industrial revenue bond financing for a US subsidiary.
Represented a Canadian bank in connection with $12 million secured loans guaranteed by US subsidiaries of a Canadian company.
Represented a Canadian bank in connection with CAD $5 million loan guaranteed by the US subsidiary of a Canadian company.
Corporate Reorganizations: Represented major French companies (including one CAC 40 company) in connection with the implementation of tracking stock structures for their respective U.S. holding company.
Represented a major French company (CAC 40) in connection with a complete reorganization of the worldwide holdings of a major US subsidiary in order to enable a $1 billion divestiture
a $650 million divestiture.
Represented a major French company (CAC 40) in connection with the recapitalization of its US holding company (over $1 billion).
Represented a major French company (CAC 40) in connection with the spin-off of a major US subsidiary to a joint venture ($165 million).
Represented a major French company (CAC 40) in connection with the reorganization of its US activities.
Represented two major French companies (CAC 40) in connection with the spin-off of certain jointly acquired US assets to their respective US subsidiaries.
Represented several Canadian companies in connection with double dip -driven reorganizations of their US activities.
